Experts urge health regulators to approve ‘turning point’ dementia drugs

As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

What impact will the Alzheimer’s drug donanemab have?

Health regulators are being urged to rapidly approve two gamechanging dementia drugs in order to ensure millions of people who could benefit are not “left in limbo”, after yet more stunning trial data.

The final results from a landmark study confirmed that donanemab, made by Eli Lilly, slowed cognitive decline in Alzheimer’s patients by 35%. Trial results published last year showed that a second drug, lecanemab, made by Eisai and Biogen, reduced the rate by 27%.

Continue reading…

8309

614

Subscribe

Connect with

Login

I allow to create an account

When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.

DisagreeAgree

Notify of

new follow-up comments new replies to my comments

Label

{} [+]

Name*

Email*

Website

I allow to create an account

When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.

DisagreeAgree

Label

{} [+]

Name*

Email*

Website

0 Comments

Inline Feedbacks

View all comments